MA32003B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA32003B1
MA32003B1 MA32991A MA32991A MA32003B1 MA 32003 B1 MA32003 B1 MA 32003B1 MA 32991 A MA32991 A MA 32991A MA 32991 A MA32991 A MA 32991A MA 32003 B1 MA32003 B1 MA 32003B1
Authority
MA
Morocco
Prior art keywords
viral vector
seq
relates
protein
malaria
Prior art date
Application number
MA32991A
Other languages
Arabic (ar)
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32003B1 publication Critical patent/MA32003B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un vecteur adénoviral simien c7 défectif pour la réplication, encodant une protéine incluant une protéine cs de p. Falciparum ou un fragment de celle-ci, ainsi qu'illustré, par exemple, dans la seq id : 1 ou la seq id : 3. L'invention porte également sur des procédés de préparation dudit vecteur viral et sur l'utilisation de celui-ci dans le traitement / la prévention des infections du type paludisme. L'invention concerne également des compositions, des vaccins et des kits contenant ledit vecteur viral. Dans un aspect, l'invention recourt à un vecteur viral c7 de synthèse. Le vecteur viral c7 selon l'invention peut être administré conjointement ou formulé conjointement à un antigène du paludisme tel que rtss, éventuellement en présence d'un adjuvant incluant par exemple un 3d-mpl et/ou une saponine qs-21.
MA32991A 2007-12-06 2010-07-05 Vaccin MA32003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06
PCT/EP2008/066762 WO2009071613A2 (fr) 2007-12-06 2008-12-04 Vaccin

Publications (1)

Publication Number Publication Date
MA32003B1 true MA32003B1 (fr) 2011-01-03

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32991A MA32003B1 (fr) 2007-12-06 2010-07-05 Vaccin

Country Status (20)

Country Link
EP (1) EP2227550A2 (fr)
JP (1) JP2011505796A (fr)
KR (1) KR20100108544A (fr)
CN (1) CN101939438A (fr)
AR (1) AR069568A1 (fr)
AU (1) AU2008333208A1 (fr)
BR (1) BRPI0819889A2 (fr)
CA (1) CA2707245A1 (fr)
CL (1) CL2008003614A1 (fr)
CO (1) CO6300795A2 (fr)
CR (1) CR11537A (fr)
DO (1) DOP2010000164A (fr)
IL (1) IL205953A0 (fr)
MA (1) MA32003B1 (fr)
MX (1) MX2010006207A (fr)
PE (1) PE20091106A1 (fr)
TW (1) TW200938633A (fr)
UY (1) UY31510A1 (fr)
WO (1) WO2009071613A2 (fr)
ZA (1) ZA201003851B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
NZ539509A (en) * 2002-10-23 2008-05-30 Glaxosmithkline Biolog Sa Priming vaccine comprising a polynucleotide encoding at least one first malarial antigen and a boosting vaccine comprising at least one polypeptide comprising at least one second malarial antigen having at least one epitope in common with the first malarial antigen of the priming vaccine
SG156535A1 (en) * 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
WO2005063805A1 (fr) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps dirige contre la zone de terminus amino de la proteine circumsporozoite, pour prevenir l'apparition d'infections paludeennes
CA2553541C (fr) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Porteurs de vaccin adenoviral de chimpanze
WO2006040334A1 (fr) * 2004-10-14 2006-04-20 Crucell Holland B.V. Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007110409A1 (fr) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
BRPI0715581A2 (pt) * 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
DK2137210T3 (en) * 2007-03-02 2017-01-30 Glaxosmithkline Biologicals Sa Hitherto unknown method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
CL2008003614A1 (es) 2010-01-15
TW200938633A (en) 2009-09-16
WO2009071613A3 (fr) 2009-08-13
CN101939438A (zh) 2011-01-05
WO2009071613A2 (fr) 2009-06-11
AR069568A1 (es) 2010-02-03
DOP2010000164A (es) 2010-07-31
IL205953A0 (en) 2010-11-30
JP2011505796A (ja) 2011-03-03
CO6300795A2 (es) 2011-07-21
BRPI0819889A2 (pt) 2015-06-16
CR11537A (es) 2010-08-18
KR20100108544A (ko) 2010-10-07
PE20091106A1 (es) 2009-08-24
AU2008333208A1 (en) 2009-06-11
CA2707245A1 (fr) 2009-06-11
ZA201003851B (en) 2012-11-28
MX2010006207A (es) 2010-10-04
UY31510A1 (es) 2009-08-03
EP2227550A2 (fr) 2010-09-15

Similar Documents

Publication Publication Date Title
MA29714B1 (fr) Vaccin
MA33449B1 (fr) Antigènes recombinants du vrs
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
MA30670B1 (fr) Vaccins contre le paludisme
NZ612315A (en) Compositions for immunising against staphylococcus aureus
EA201001189A1 (ru) Вакцинные композиции, содержащие сапониновый адъювант
MX2008013993A (es) Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
DE60328108D1 (de) Iscom-zubereitung und ihre verwendung
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
CO5700790A2 (es) Composiciones de vacuna que comprenden una interleucina 18 y sistema de adyuvante de saponina
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
MA32003B1 (fr) Vaccin
RU2012125254A (ru) Составы антитела
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
MA29601B1 (fr) Vaccin antipaludeen
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
WO2006062807A3 (fr) Compositions a immunogenicite renforcee
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
MA32018B1 (fr) Vaccin
JP2017508006A5 (fr)
DOP2010000189A (es) Vacunas contra la malaria
BR0109846A (pt) Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
KR20150032266A (ko) Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof